Interleukin-6 as a key player in systemic inflammation and joint destruction

Autoimmunity Reviews

Volumn 8, Issue 7, 2009, Pages 538-542

  Fonseca, J E ^a,b   Santos, M J ^a,c   Canhao H ^a,b   Choy, E ^d  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Arthritis; Bone; Inflammation; Interleukin 6; Tocilizumab

Indexed keywords

AMINOTRANSFERASE; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LIPID; LIVER ENZYME; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

AMYLOIDOSIS; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOIMMUNE DISEASE; BONE EROSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; INFECTION; INFLAMMATION; JOINT DESTRUCTION; LABORATORY TEST; LIPID PROFILE; NEUTROPENIA; NONHUMAN; PLEIOTROPY; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYNOVITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6;

EID: 67349104400     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.01.012     Document Type: Review

References (40)

1. Kishimoto T. The biology of interleukin-6. Blood 74 (1989) 1-10
2. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology. 11 (2006) 19-26
3. Yoshizaki K., Nakagawa T., Kaieda T., Muraguchi A., Yamamura Y., and Kishimoto T. Induction of proliferation and Igs-production in human B leukemic cells by antiimmunoglobulins and T cell factors. J Immunol 128 (1982) 1296-1301
4. Veldhoen M., Hocking J.R., Atkins J.C., Locksley M.R., and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
5. Akira S., and Kishimoto T.T. Interleukin-6 in biology and medicine. Adv Immunol 54 (1993) 1-78
6. Castell J.V., Gomez-Lechon M.J., David M., Hirano T., Kishimoto T., and Heinrich P.C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232 (1988) 347-350
7. Veldhuis G.J., Willemse P.H.B., Sleijfer D.T., van der Groaf W.T.A., Groen H.J.M., Limburg P.C., et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13 (1995) 2585-2593
8. Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48 (2003) 1521-1529
9. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., et al. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 6 (2000) 583-588
10. Guerne P.A., Zuraw B.L., Vaughan J.H., Carson D.A., and Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 83 (1989) 585-592
11. Houssiau F.A., Devogelaer J.P., Van Damme J., de Deuxchaisnes C.N., and Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31 (1988) 784-788
12. Madhok R., Crilly A., Watson J., and Capell H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52 (1993) 232-234
13. Pawlik A., Wrzesniewska J., Florczak M., Gawronska-Szklarz B., and Herczynska M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 34 (2005) 109-113
14. Atsumi T., Ishihara K., Kamimura D., Ikushima H., Ohtani T., Hirota S., et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196 (2002) 979-990
15. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41 (1998) 2117-2121
16. Mihara M., Kotoh M., Nishimoto N., Oda Y., Kumagai E., Takagi N., et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 98 (2001) 319-326
17. Rothwell N.J., Busbridge N.J., Lefeuvre R.A., and Hardwick A.J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol 69 (1991) 1465-1469
18. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
19. Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., and Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84 (1987) 9035-9039
20. Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P., and Burstein S.A. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol 20 (1990) 1927-1931
21. Tsigos C., Papankolaou D.A., Defensor R., Mitsiadis C.S., Kyrou I., and Chrousos G.P. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66 (1997) 54-62
22. Heliovaara M.K., Teppo A.M., Karonen S.L., Tuominen J.A., and Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab 7 (2005) 729-736
23. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
24. Glund S., Deshmukh A., Long Y.C., Moller T., Koistinen H.A., Caidahl K., Zierath J.R., et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56 (2007) 1630-1637
25. Cutolo M., and Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev 7 (2008) 223-228
26. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 340 (1999) 115-126
27. Ridker P.M., Rifai N., Pfeifer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 1767-1772
28. Olopien B., Hyper M., Kowalski J., Belowski D., Madej A., Zieliński M., et al. A new immunological marker of atherosclerotic injury of arterial wall. Res Commun Mol Pathol Pharmacol 109 (2001) 241-248
29. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 108 (2003) 2317-2322
30. Manolagas S.C., and Jilka R.L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332 (1995) 305-311
31. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 90 (1993) 11924-11928
32. Pottratz S., Bellido T., Mocharla H., Crabb D., and Manolagas S.C. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 93 (1994) 944-950
33. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257 (1992) 88-91
34. Choy E.H., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46 (2002) 3143-3150
35. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50 (2004) 1761-1769
36. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Bröll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
37. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008) 987-997
38. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008) 2968-2980
39. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
40. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167